{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed-Platinum&page=7", "query": { "intervention": "Pemetrexed-Platinum", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 313, "total_pages": 32, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed-Platinum&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed-Platinum&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T04:46:19.381Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00799240", "title": "MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Arm A: Pemetrexed Cisplatin", "type": "DRUG" }, { "name": "Arm B Pemetrexed, Cisplatin and MK-0646", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2009-06", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2014-11-07", "last_synced_at": "2026-10-07T04:46:19.381Z", "location_count": 4, "location_summary": "Hutchinson, Kansas • Kansas City, Kansas • Topeka, Kansas + 1 more", "locations": [ { "city": "Hutchinson", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Topeka", "state": "Kansas" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00799240" }, { "nct_id": "NCT04866017", "title": "A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2021-06-17", "completion_date": "2023-10-17", "has_results": true, "last_update_posted_date": "2024-10-31", "last_synced_at": "2026-10-07T04:46:19.381Z", "location_count": 1, "location_summary": "Bolivar, Missouri", "locations": [ { "city": "Bolivar", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04866017" }, { "nct_id": "NCT03138889", "title": "Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "NKTR-214", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2017-06-09", "completion_date": "2022-08-24", "has_results": true, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-10-07T04:46:19.381Z", "location_count": 23, "location_summary": "Fayetteville, Arkansas • San Francisco, California • Aurora, Colorado + 19 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03138889" }, { "nct_id": "NCT03664024", "title": "Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2018-10-30", "completion_date": "2021-11-05", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-10-07T04:46:19.381Z", "location_count": 3, "location_summary": "Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03664024" }, { "nct_id": "NCT03520686", "title": "Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "NAI + Pembrolizumab", "type": "DRUG" }, { "name": "NAI + Nivolumab + Ipilimumab", "type": "DRUG" }, { "name": "NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI", "type": "DRUG" }, { "name": "Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI", "type": "DRUG" }, { "name": "Carboplatin + Nab-paclitaxel + Atezolizumab + NAI", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel", "type": "DRUG" }, { "name": "Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin and Nab-paclitaxel plus Atezolizumab", "type": "DRUG" }, { "name": "Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2018-05-18", "completion_date": "2025-10-13", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-07T04:46:19.381Z", "location_count": 31, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "El Segundo", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03520686" }, { "nct_id": "NCT02983045", "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer", "Urothelial Carcinoma", "Triple Negative Breast Cancer", "HR+/HER2- Breast Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Dose Escalation Doublet: Combination of NKTR-214 + nivolumab", "type": "DRUG" }, { "name": "Dose Expansion Doublet: Combination of NKTR-214 + nivolumab", "type": "DRUG" }, { "name": "Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab", "type": "DRUG" }, { "name": "Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 557, "start_date": "2016-12-19", "completion_date": "2022-04-28", "has_results": true, "last_update_posted_date": "2023-03-13", "last_synced_at": "2026-10-07T04:46:19.381Z", "location_count": 22, "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02983045" }, { "nct_id": "NCT02087241", "title": "Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer" ], "interventions": [ { "name": "AZD1775", "type": "DRUG" }, { "name": "AZD1775 Matching Placebo", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2014-03", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-10-07T04:46:19.381Z", "location_count": 8, "location_summary": "Englewood, Colorado • Fort Myers, Florida • Orlando, Florida + 5 more", "locations": [ { "city": "Englewood", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02087241" }, { "nct_id": "NCT00461786", "title": "A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 51, "start_date": "2004-09", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2009-12-04", "last_synced_at": "2026-10-07T04:46:19.381Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00461786" }, { "nct_id": "NCT05298423", "title": "Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "pembrolizumab/vibostolimab", "type": "BIOLOGICAL" }, { "name": "durvalumab", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "thoracic radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 610, "start_date": "2022-05-03", "completion_date": "2026-06-15", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-07T04:46:19.381Z", "location_count": 21, "location_summary": "Long Beach, California • Los Angeles, California • Hollywood, Florida + 18 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05298423" }, { "nct_id": "NCT01336842", "title": "Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Panobinostat, Cisplatin, Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2011-04", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2018-01-09", "last_synced_at": "2026-10-07T04:46:19.381Z", "location_count": 2, "location_summary": "Sacramento, California • Detroit, Michigan", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01336842" } ] }